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116Dear Editors:
We read with interest the article published by
Debes et al.1 These investigators observed that, in patients
with hepatitis C-related cirrhosis, the serum levels of
inflammatory cytokines before treatment and their modi-
fication with direct-acting antiviral (DAA) were associated
with occurrence or recurrence of hepatocellular carcinoma
(HCC). An additional hypothesis may be a dysregulation of
the antitumor response after the sharp decrease in the
hepatitis C viral load induced by DAA therapy, promoting
tumor development. We evaluated whether changes in
neutrophil and lymphocyte counts during treatment with
DAA can be associated with HCC development. Retro-
spective laboratory data obtained at baseline and at the
end of treatment in 308 consecutive patients with
hepatitis C-related cirrhosis, but without previous HCC,
were evaluated. Patients were treated with different
approved DAA regimens at different centers in the
metropolitan area of Bologna, Italy, between March 2015
and August 2016. After a median follow-up of 10.5 months
from the end of treatment, HCC was detected and
confirmed by 2 independent imaging techniques or
biopsy in 23 of 308 patients (7.24%). A significant
increase in neutrophil counts (2.88  109/L ± 1.21 vs
3.32  109/L ± 1.32; P ¼ .0002) and a significant decrease
in lymphocyte counts (1.61  109/L ± 0.84 vs 1.46 
109/L ± 0.79; P ¼ .037) were observed between baseline
and the end of treatment. We evaluated the difference in
neutrophils and lymphocytes between baseline and the
end of treatment in patients with or without HCC occur-
rence. In patients with HCC development (n ¼ 23), we
observed a significant increase in neutrophils (2.35 
109/L ± 1.02 vs 3.11  109/L ± 1.26; P ¼ .033) and
decrease in lymphocytes (1.78  109/L ± 1.07 vs 0.99 
109/L ± 0.53; P ¼ .003) during treatment. In patients
without HCC development (n ¼ 285), there was a similar
trend, but it was not statistically significant (neutrophils:
3.00  109/L ± 1.26 vs 3.23  109/L ± 1.41 [P ¼ .08];
lymphocytes: 1.66  109/L ± 0.86 vs 1.54  109/L ± 0.85
[P ¼ .14]).COR 5.5.0 DTD  YGAST61832_prooIt is well-known that neutrophils promote adhesion and
seeding of distant organ sites through the secretion of
circulating growth factors such as vascular endothelial
growth factor and proteases.2,3 In contrast, cytotoxic
T lymphocytes play a crucial role in tumor defense inducing
tumor cell death and inhibiting tumor cell proliferation and
migration, thereby dictating the host’s immune response to
malignancy.2 Our study suggests that, during DAA treat-
ment, there is a significant imbalance between lymphocytes
and neutrophils that is particularly evident in subjects
developing HCC. This imbalance may result in an unfavor-
able microenvironment that favors the growth of cancer
cells. Thus, inflammation may induce changes in the cancer
microenvironment favoring cancer progression.2 Based on
these observations, we suppose that treatment with DAA, in
some patients, can induce the deregulation of immune de-
fenses characterized by an increase of vascular endothelial
growth factor, leading to an early development of HCC, as
suggested by Debes et al1 and by Villani et al5 in a recently
published study.
In this complex context, evaluation of changes in
neutrophil and lymphocyte counts during treatment with
DAAs adds a simple and easily to obtain information about
the patient’s inflammatory state and their possible risk of
developing HCC after DAA treatment. Q
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